↓ Skip to main content

Cochrane Database of Systematic Reviews

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease

Overview of attention for article published in Cochrane database of systematic reviews, October 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
7 X users

Citations

dimensions_citation
72 Dimensions

Readers on

mendeley
162 Mendeley
citeulike
1 CiteULike
Title
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non‐diabetic chronic kidney disease
Published in
Cochrane database of systematic reviews, October 2011
DOI 10.1002/14651858.cd007751.pub2
Pubmed ID
Authors

Pawana Sharma, Rachel C Blackburn, Claire L Parke, Keith McCullough, Angharad Marks, Corri Black

Abstract

Chronic kidney disease (CKD) is a long term condition that occurs as a result of damage to the kidneys. Early recognition of CKD is becoming increasingly common due to widespread laboratory estimated glomerular filtration rate (eGFR) reporting, raised clinical awareness, and international adoption of Kidney Disease Outcomes Quality Initiative (K/DOQI) classification. Early recognition and management of CKD affords the opportunity not only to prepare for progressive kidney impairment and impending renal replacement therapy, but also for intervening to reduce the risk of progression and cardiovascular disease. Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are two classes of antihypertensive drugs that act on the renin-angiotensin-aldosterone system. Beneficial effects of ACEi and ARB on renal outcomes and survival in people with a wide range of severity of renal impairment have been reported; however, their effectiveness in the subgroup of people with early CKD (stage 1 to 3) is less certain.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 162 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Austria 1 <1%
Brazil 1 <1%
Unknown 159 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 13%
Researcher 19 12%
Student > Bachelor 18 11%
Student > Ph. D. Student 15 9%
Student > Postgraduate 14 9%
Other 28 17%
Unknown 47 29%
Readers by discipline Count As %
Medicine and Dentistry 71 44%
Nursing and Health Professions 8 5%
Pharmacology, Toxicology and Pharmaceutical Science 8 5%
Agricultural and Biological Sciences 3 2%
Psychology 3 2%
Other 16 10%
Unknown 53 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2021.
All research outputs
#2,100,995
of 26,086,865 outputs
Outputs from Cochrane database of systematic reviews
#4,297
of 13,187 outputs
Outputs of similar age
#10,050
of 147,110 outputs
Outputs of similar age from Cochrane database of systematic reviews
#27
of 129 outputs
Altmetric has tracked 26,086,865 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,187 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 147,110 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 129 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.